Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CJ-023, 423 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 3 | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | 75 mg BID |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CJ-023,423 | DRUG | 75 mg BID |
| placebo | DRUG | placebo |
| naproxen | DRUG | naproxen |
Inclusion Criteria: * Is a healthy adult 18 to 75 years of age, inclusive; healthy is defined as no clinically relevant abnormalities identified as detailed medical history, full physical examination, including blood pressure \[BP\] and pulse rate \[PR\]measurement, 12-lead electrocardiogram \[ECG\...
CJ-023,423 is an investigational small molecule being studied for osteoarthritis. It is being developed by Pfizer, Inc. (PFE). The drug is currently in Phase 1 clinical development and is not approved by the FDA.
The molecular target of CJ-023,423 has not been disclosed in available information. The drug is a small molecule being evaluated for its effect on the incidence of stomach ulcers in patients with osteoarthritis.
CJ-023,423 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
CJ-023,423 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
CJ-023,423 has one completed Phase 1 trial, NCT00392080, titled "A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers." The trial enrolled 340 participants with osteoarthritis in the United States and was placebo-controlled, randomized, and double-blind.
No alternative names for CJ-023,423 have been reported. The drug is identified solely by its code name CJ-023,423 in clinical trial records.